Woodline Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Woodline Partners’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-133,700	Closed	-$9.11M	–	984
2022 Q3	$9.11M	Sell	133,700 -813,914	-86%	-$44.9M	0.13%	212
2022 Q2	$30.3M	Buy	+947,614	New	+$27.7M	0.47%	53
2021 Q4	–	Sell	-161,940	Closed	-$4.13M	–	847
2021 Q3	$4.13M	Buy	+161,940	New	+$4.76M	0.07%	284

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Woodline Partners's GBT Position: Q4 2022 in Review

Woodline Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 133,700 shares — an estimated $9.11M sold.

Woodline Partners first reported a position in GBT in Q3 2021 and held it in 3 quarters. The position peaked at $30.3M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Woodline Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Woodline Partners sold 133,700 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $9.11M.
Woodline Partners first reported a position in Global Blood Therapeutics, Inc. in Q3 2021 and held it in 3 quarters.
Woodline Partners's Global Blood Therapeutics, Inc. position peaked at $30.3M in Q2 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Woodline Partners's 13F filing for Q4 2022, filed 14 Feb 2023.